Hims & Hers Health (NYSE:HIMS) Insider Sells $118,808.28 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,812 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $118,808.28. Following the transaction, the insider directly owned 308,831 shares in the company, valued at approximately $7,625,037.39. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hims & Hers Health Price Performance

HIMS opened at $21.99 on Friday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a 50 day moving average of $22.80 and a two-hundred day moving average of $36.75. The company has a market cap of $5.01 billion, a P/E ratio of 43.13, a P/E/G ratio of 2.71 and a beta of 2.55. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 EPS. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter valued at about $26,000. Quent Capital LLC acquired a new position in shares of Hims & Hers Health in the third quarter worth about $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health in the third quarter valued at about $28,000. Finally, Bogart Wealth LLC boosted its holdings in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Evercore set a $24.00 price objective on Hims & Hers Health in a research note on Tuesday, February 24th. Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and increased their target price for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Monday, March 9th. Leerink Partners boosted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $31.29.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.